February 25th 2024
Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.
February 22nd 2024
The decision by the FDA is a step closer to omalizumab’s potential approval, making it the potential first medicine to reduce reactions to many different food allergens after accidental exposure.
Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.
This research shows that a basophil activation test can support decision-making by clinicians when re-introduction of baked eggs in patients with allergies is a treatment being considered.
This analysis on a larger study population led to results which add useful data to the growing literature on sesame thresholds and may even help to assess sesame safe doses used in risk management.
This expanded upon the limited data available on risks of precautionary allergen label food introduction for those with allergies, the results of which suggest new possibilities for future allergy management.
New data indicated the development of allergy was not affected by mothers’ consumption of eggs in the very early neonatal period, expanding the body of research exploring food sensitization.
New data on oral immunotherapy to food allergens shows promise for the treatment, though more information with standard interventions and regimens is needed to gain certainty on the efficacy and safety.
Future studies of socioeconomic factors and environmental elements contributing may help to further explain the causes of food allergies and inform targeted interventions and management.
This new data indicates that the peanut patch was efficacious and safe in children with peanut allergies in this age bracket, expanding the body of research on desensitization for toddlers and young children.
"You want to be empowering children to be proactive and managing their medical condition in the healthiest, safest possible way," Dr. Christopher Warren said in an interview at AAAAI 2023.
Dr. Christopher Warren discusses the study he presented at AAAAI 2023 Annual Meeting that found 98% of participants experienced added anxiety when traveling due to their food allergy, with a "lamentingly high number" of negative experiences.